MERCURY PHARMACEUTICALS LIMITED

1. MERCURY PHARMACEUTICALS LIMITED 2012-03-26 → present
2. MERCURY PHARMA LIMITED 2012-03-20 → 2012-03-26
3. GOLDSHIELD PHARMACEUTICALS LTD. 1992-10-02 → 2012-03-20
4. CHECKEURO LIMITED 1991-06-12 → 1992-10-02

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

FRS 101

Reporting scope

Standalone (parent only)

Auditor

PricewaterhouseCoopers LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“In assessing the ability of the Company to continue as a going concern, the directors have taken account of the profit in 2024 of £3,017, the cumulative profits of £26,838, and the Company's net current assets and net asset position of £27,569 at 31 December 2024. The Company's Intermediate Holding Company, APHL has provided the Company with a letter of support indicating its intention to provide the financial support required for a period of at least 12 months from the date these financial statements are approved... Accordingly, the directors consider it appropriate to prepare these entity financial statements on a going concern basis.”

Group structure

1. MERCURY PHARMACEUTICALS LIMITED · parent
   1. Amdipharm Mercury (Australia) Pty Limited 1% · Australia

Significant events

• “In 2023, the Group has conducted its first materiality assessment and reshaped its ESG roadmap. During 2024, the Group conducted a double materiality assessment exercise in accordance with the European Union's Corporate Sustainability Reporting Directive ("CSRD").”
• “On 25 October 2024, the Group, through its wholly owned subsidiary Cidron Aida Finco SaRL, entered into a senior facilities agreement pursuant to which a syndicate of lenders made available a secured term loan at par for the principal amount of €725 million.”
• “On 10 October 2016, the UK Competition and Markets Authority ("CMA") commenced an investigation into ADVANZ PHARMA Corp. Limited ("ADVANZ PHARMA") in relation to the pricing of liothyronine tablets in the UK...On 8 May 2025, the Court of Appeal issued its judgment in which it upheld the CMA's findings against the Company and the Group. On 5 June 2025 the Company and the Group filed an application with the Court of Appeal seeking permission to appeal.”
• “On 8 April 2025, the Group successfully completed the refinancing of its existing €650 million 5% senior secured notes due 2028 and £335 million 6.25% senior secured notes due 2028. This refinancing was effected through the issuance of €615 million in 7% senior secured notes due 2031 and £250 million in 9.125% senior secured notes due 2031, together with a new €165 million term loan facility.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

2

last 12 months

Capital events

0

last 24 months

Officers appointed

0

last 12 months

Officers resigned

0

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.

• Turnover

  +17.8%

  £83,305,000 → £98,142,000

• Cash

  -88%

  £7,178,000 → £862,000

• Net assets

  +12.3%

  £24,552,000 → £27,569,000

• Employees

  -50%

  4 → 2

• Operating profit

  -16.9%

  £3,473,000 → £2,885,000

• Profit before tax

  -15.3%

  £3,560,000 → £3,017,000

• Wages

  -70.2%

  £309,000 → £92,000

Each % is (latest − prior) ÷ |prior| for the line item as filed. Periods don't have to be exactly 12 months apart — a long or short period (typical around incorporation or year-end changes) will distort the comparison. Lines a company doesn't report are omitted. About these numbers